Pertussis cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
===Cost Effectiveness of Vaccination=== | ===Cost Effectiveness of Vaccination=== | ||
Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. <ref name="17296470"{{cite journal |vauthors=Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA |title=Cost effectiveness of pertussis vaccination in adults |journal=Am J Prev Med |volume=32 |issue=3 |pages=186–193 |year=2007 |pmid=17296470 |doi=10.1016/j.amepre.2006.10.016 |url=}}</ref> | Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. <ref name="17296470">{{cite journal |vauthors=Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA |title=Cost effectiveness of pertussis vaccination in adults |journal=Am J Prev Med |volume=32 |issue=3 |pages=186–193 |year=2007 |pmid=17296470 |doi=10.1016/j.amepre.2006.10.016 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 17:46, 7 January 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Luke Rusowicz-Orazem, B.S.
|
Pertussis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pertussis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Pertussis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pertussis cost-effectiveness of therapy |
Cost Effectiveness of Therapy
- Given the morbidity of of Pertussis, the cost-effectiveness of treatment is substantial.
- A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773.[1]
- If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.[1]
Cost Effectiveness of Vaccination
Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. Invalid <ref> tag; name cannot be a simple integer. Use a descriptive title